SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Campo, Rafael; DeJesus, Edwin; Bredeek, U. Fritz; Henry, Keith; Khanlou, Homayoon; Logue, Ken; Brinson, Cynthia; Benson, Paul M.; Dau, Lauren; Wang, H.; White, Kirsten; Flaherty, John F.; Fralich, Todd; Guyer, Bill; Piontkowsky, David

doi:10.1093/cid/cis1203

Cited by 42 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Switch from stavudine-containing ART to TDF results in reductions in total cholesterol, LDL-and HDLcholesterol, and triglycerides, an effect not observed in those who switched to ABC [56], with similar observations in studies examining a switch from zidovudine-or ABC-containing ART to TDF [57,58]. In fact, TDF may have an independent lipid-lowering effect; the addition of TDF to a stable ART regimens was associated with significant reductions in total cholesterol, non-HDLand LDL-cholesterol compared with placebo [59], although the exact underlying mechanisms of this lipid-lowering effect remain to be determined.…”

Section: Nucleoside and Nucleotide Reverse Transcriptase Inhibitorssupporting

confidence: 58%

Dyslipidemia, Atherosclerosis and Cardiovascular Disease: An Increasingly Important Triad in an Aging Population Living with HIV

2013

View full text Add to dashboard Cite

As a result of major advances in the management of HIV over the last two decades, patients living with HIV are now encountering comorbidities commonly associated with aging. Cardiovascular disease is the leading cause of death worldwide. As the population living with HIV ages, understanding cardiovascular disease in the setting of HIV is of increasing importance. This review examines the complex interplay between cardiovascular disease, HIV infection and the drugs used to treat it, with particular emphasis on the contribution of dyslipidemia.

show abstract

Section: Nucleoside and Nucleotide Reverse Transcriptase Inhibitorssupporting

confidence: 58%

Dyslipidemia, Atherosclerosis and Cardiovascular Disease: An Increasingly Important Triad in an Aging Population Living with HIV

2013

View full text Add to dashboard Cite

show abstract

“…Abacavir-lamivudine was recently compared to tenofoviremtricitabine, combined either with efavirenz or atazanavir- ritonavir, reporting higher lipid levels in the abacavir group but similar TC/HDL ratio [78], findings beings also reported in other studies [79][80][81]. However, decreases in TG and increases in HDL-C were greater with abacavir/ lamivudine than with tenofovir/emtricitabine when combined with raltegravir [82].…”

Section: Metabolic and Thrombotic Complications Associated With Cartmentioning

confidence: 60%

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

2015

View full text Add to dashboard Cite

With more effective and widespread antiretroviral treatment, the overall incidence of AIDS- or HIV-related death has decreased dramatically. Consequently, as patients are aging, cardiovascular disease (CVD) has emerged as an important cause of morbidity and mortality in the HIV population. The incidence of CVD overall in HIV is relatively low, but it is approximately 1.5-2-fold higher than that seen in age-matched HIV-uninfected individuals. Multiple factors are believed to explain this excess in risk such as overrepresentation of traditional cardiovascular risk factors (particularly smoking), toxicities associated with cumulative exposure to some antiretroviral agents, together with persistent chronic inflammation, and immune activation associated with HIV infection. Tools are available to calculate an individual's predicted risk of CVD and should be incorporated in the regular follow-up of HIV-infected patients. Targeted interventions to reduce this risk must be recommended, including life-style changes and medical interventions that might include changes in antiretroviral therapy.

show abstract

“…Conversely, it has become apparent that TDF has a lipid-lowering effect [15, 80], and though this has beneficial effects on calculated cardiovascular risk we are presently lacking good data on actual influence on clinical cardiac events.…”

Section: Tolerability and Toxicitymentioning

confidence: 99%

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Ustianowski

Arends

2015

Infect Dis Ther

View full text Add to dashboard Cite

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-015-0070-1) contains supplementary material, which is available to authorized users.

show abstract

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Cited by 42 publications

References 14 publications

Dyslipidemia, Atherosclerosis and Cardiovascular Disease: An Increasingly Important Triad in an Aging Population Living with HIV

Dyslipidemia, Atherosclerosis and Cardiovascular Disease: An Increasingly Important Triad in an Aging Population Living with HIV

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Contact Info

Product

Resources

About